Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
Angela I. Schriek, Marlies M. van Haaren, Meliawati Poniman, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20

Showing 20 citing articles:

Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication
Ana Borrajo
Life (2025) Vol. 15, Iss. 2, pp. 276-276
Open Access | Times Cited: 1
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Vaishali Verma, N. D. Sinha, A. Raja
mAbs (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
Philip J. M. Brouwer, Aleksandar Antanasijevic, Adam J. Ronk, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 12, pp. 1759-1772.e12
Open Access | Times Cited: 35
Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing
Steven W. de Taeye, Angela I. Schriek, Jeffrey C. Umotoy, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 5
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
Laura Radić, Kwinten Sliepen, Victor Yin, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106540-106540
Open Access | Times Cited: 13
Next-generation bNAbs for HIV-1 cure strategies
Angela I. Schriek, Yoann Aldon, Marit J. van Gils, et al.
Antiviral Research (2023) Vol. 222, pp. 105788-105788
Open Access | Times Cited: 13
CXCR4 Is a Potential Target for Anti-HIV Gene Therapy
Appolinaria K. Prokopovich, Irina S. Litvinova, Alexandra E. Zubkova, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1187-1187
Open Access | Times Cited: 4
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses
Noelia Silva-Pilipich, Ester Blanco, Teresa Lozano, et al.
Cancer Letters (2023) Vol. 561, pp. 216139-216139
Open Access | Times Cited: 11
Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein
Laura Radić, Anna Offersgaard, Tereza Kadavá, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 15
Open Access
Design of nanobody targeting SARS-CoV-2 spike glycoprotein using CDR-grafting assisted by molecular simulation and machine learning
Matheus Ferraz, Wenny Camilla dos Santos Adan, Tayná Evily de Lima, et al.
PLoS Computational Biology (2025) Vol. 21, Iss. 4, pp. e1012921-e1012921
Open Access
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation
Soyeon Yi, Kyunghee Noh, Hye-Ran Kim, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection
P. Hahn, Maurício A. Martins
Journal of Virus Eradication (2023) Vol. 9, Iss. 1, pp. 100316-100316
Open Access | Times Cited: 8
Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses
Karlijn van der Straten, Denise Guerra, Gius Kerster, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 8, pp. e1012453-e1012453
Open Access | Times Cited: 2
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Zhihong Wang, Zhuangzhuang Shi, Xiaochen Liao, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
Inhibition of HIV-1 replication by nanobodies targeting tetraspanin CD9
Jeffrey C. Umotoy, Pascal Z. Kroon, S. F. Paul Man, et al.
iScience (2024) Vol. 27, Iss. 10, pp. 110958-110958
Open Access | Times Cited: 1
Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions
Angela I. Schriek, David Falck, Manfred Wuhrer, et al.
Antiviral Research (2024), pp. 106015-106015
Open Access | Times Cited: 1
Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression
Marloes Grobben, Margreet Bakker, Angela I. Schriek, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 12, pp. e1012739-e1012739
Open Access | Times Cited: 1
Structural insights into the rational design of a nanobody that binds with high affinity to the SARS-CoV-2 spike variant
Keishi Yamaguchi, Itsuki Anzai, Ryota Maeda, et al.
The Journal of Biochemistry (2022) Vol. 173, Iss. 2, pp. 115-127
Open Access | Times Cited: 3
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
Laura Radić, Kwinten Sliepen, Victor Yin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Delivery of Fc-fusion Protein by a Recombinant Newcastle Disease Virus Vector
Zenglei Hu, Jianing Feng, Jing Deng, et al.
Applied Biochemistry and Biotechnology (2022) Vol. 195, Iss. 3, pp. 2077-2092
Closed Access
Page 1

Scroll to top